Cargando…
The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study
BACKGROUND: The aim of this study is to investigate the prognostic relevance of the best objective response of metastatic target lesions during sunitinib treatment in patients with metastatic renal cell carcinoma. METHODS: Radiographic analysis of the best objective response according to the Respons...
Autores principales: | Miyake, Makito, Kuwada, Masaomi, Hori, Shunta, Morizawa, Yosuke, Tatsumi, Yoshihiro, Anai, Satoshi, Hosokawa, Yukinari, Hayashi, Yoshiki, Tomioka, Atsushi, Otani, Takeshi, Otsuka, Kenji, Nakagawa, Yoshinori, Nakai, Yasushi, Samma, Shoji, Tanaka, Nobumichi, Fujimoto, Kiyohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748467/ https://www.ncbi.nlm.nih.gov/pubmed/26861149 http://dx.doi.org/10.1186/s13104-016-1895-8 |
Ejemplares similares
-
Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient’s age and prostate volume
por: Hori, Shunta, et al.
Publicado: (2019) -
Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas
por: Morizawa, Yosuke, et al.
Publicado: (2016) -
Transperineal template-guided saturation biopsy aimed at sampling one core for each milliliter of prostate volume: 103 cases requiring repeat prostate biopsy
por: Nakai, Yasushi, et al.
Publicado: (2017) -
Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model
por: Hori, Shunta, et al.
Publicado: (2017) -
Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019)